TY - JOUR
T1 - Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia
AU - Sasaki, Koji
AU - Jabbour, Elias
AU - Cortes, Jorge
AU - Kadia, Tapan
AU - Garcia-Manero, Guillermo
AU - Borthakur, Gautam
AU - Jain, Preetesh
AU - Pierce, Sherry
AU - Daver, Naval
AU - Takahashi, Koichi
AU - O'Brien, Susan
AU - Kantarjian, Hagop
AU - Ravandi, Farhad
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - The presence of antecedent hematologic disorders at diagnosis of therapy-related acute myeloid leukemia did not affect overall survival (OS). The favorable-risk cohort had better relapse-free survival (RFS) and OS compared to the outcomes of patients in the intermediate and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. Purpose To learn whether an antecedent hematologic disorder (AHD) is associated with additional risk in patients with therapy-related acute myeloid leukemia (t-AML). Patients and Methods We reviewed data of 301 patients with newly diagnosed t-AML who sought care from January 2000 to January 2014 (183 t-AML without AHD, 118 t-AML with AHD). Overall, median follow-up was 44 months. Results The primary malignancy was non-Hodgkin lymphoma in 92 (31%), breast cancer in 80 (27%), and prostate cancer in 49 (16%). Median relapse-free survival (RFS) in t-AML without or with AHD was 10 months and 29 months, respectively (P = .032); median overall survival (OS) was 8 months and 8 months, respectively (P = .53). Multivariate analysis for OS identified older age, poor performance status, thrombocytopenia, nonfavorable cytogenetics, and lack of response as adverse factors. Conclusion The favorable-risk cohort had better RFS and OS compared to the outcomes of patients in the intermediate- and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. The presence of AHD did not affect OS.
AB - The presence of antecedent hematologic disorders at diagnosis of therapy-related acute myeloid leukemia did not affect overall survival (OS). The favorable-risk cohort had better relapse-free survival (RFS) and OS compared to the outcomes of patients in the intermediate and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. Purpose To learn whether an antecedent hematologic disorder (AHD) is associated with additional risk in patients with therapy-related acute myeloid leukemia (t-AML). Patients and Methods We reviewed data of 301 patients with newly diagnosed t-AML who sought care from January 2000 to January 2014 (183 t-AML without AHD, 118 t-AML with AHD). Overall, median follow-up was 44 months. Results The primary malignancy was non-Hodgkin lymphoma in 92 (31%), breast cancer in 80 (27%), and prostate cancer in 49 (16%). Median relapse-free survival (RFS) in t-AML without or with AHD was 10 months and 29 months, respectively (P = .032); median overall survival (OS) was 8 months and 8 months, respectively (P = .53). Multivariate analysis for OS identified older age, poor performance status, thrombocytopenia, nonfavorable cytogenetics, and lack of response as adverse factors. Conclusion The favorable-risk cohort had better RFS and OS compared to the outcomes of patients in the intermediate- and adverse-risk cohorts; the RFS and OS did not differ between intermediate- and adverse-risk cohorts. The presence of AHD did not affect OS.
KW - Acute myeloid leukemia
KW - Antecedent myelodysplastic syndrome
KW - Overall survival
KW - Relapse-free survival
KW - Therapy-related
UR - http://www.scopus.com/inward/record.url?scp=84994504823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994504823&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2016.08.015
DO - 10.1016/j.clml.2016.08.015
M3 - Article
C2 - 27601000
AN - SCOPUS:84994504823
SN - 2152-2650
VL - 16
SP - 616
EP - 624
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 11
ER -